August 7, 2017 10:32 AM EDTUpdated 07:45 PM

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name

Shehla Shakoor

Managing Director

→ Three months after the FDA rejected its tweaked cold remedy CCP-07, Vernalis says regulators have followed up by putting CCP-08 into the

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

FDA will consolidate to five 'shared services offices,' according to memo to Hill staffers

Trump’s broad tariffs exempt pharma — but for how long?

PIPEs, biopharma’s favorite financing vehicle, freeze amid market struggles

Chaotic tariff rollout leaves as many questions as answers for drugmakers

Another TIGIT trial fails as BeiGene scraps Phase 3 drug

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

FDA slams Ver­nalis with 2nd CRL in 3 months; For­mer Shkre­li com­pa­ny Kalo­Bios changes name

Managing Director

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name